Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Oct 13, 2021

SELL
$21.26 - $38.85 $3.07 Million - $5.6 Million
-144,254 Closed
0 $0
Q4 2020

Jan 19, 2021

BUY
$9.82 - $18.27 $1.42 Million - $2.64 Million
144,254 New
144,254 $2.39 Million

Others Institutions Holding CERE

About Cerevel Therapeutics Holdings, Inc.


  • Ticker CERE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 155,752,000
  • Description
  • Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...
More about CERE
Track This Portfolio

Track Lgt Capital Partners Ltd. Portfolio

Follow Lgt Capital Partners Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lgt Capital Partners Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Lgt Capital Partners Ltd. with notifications on news.